BiotechTube
Pila Pharma

Pila Pharma

Malmö, Sweden· Est.
pilapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.7M

Overview

Pila Pharma is a Swedish public biotech advancing XEN-D0501, a novel oral TRPV1 antagonist, through clinical development for metabolic diseases. The company is strategically positioning its lead candidate as a differentiated, simple oral therapy for the massive obesity and type 2 diabetes markets, aiming to capture volume where injectable therapies may face limitations. With a completed rights issue fueling new obesity studies and a management team with Novo Nordisk heritage, Pila is progressing its clinical programs while actively engaging the investment community.

Metabolic DiseasePainRare Disease

Technology Platform

Oral, potent, and selective TRPV1 (Transient Receptor Potential Vanilloid 1) receptor antagonist platform, targeting inflammation and metabolic regulation.

Funding History

2
Total raised:$5.7M
Series A$4.5M
Seed$1.2M

Opportunities

The massive and growing global obesity market, estimated to exceed $100 billion by 2030, presents a primary opportunity.
Pila's oral, small-molecule approach targets the volume segment of this market, which may prefer pills over injectable therapies.
A successful proof-of-concept in obesity could attract partnership interest from larger pharma companies seeking to diversify their metabolic portfolios.

Risk Factors

The key risk is the unproven efficacy of the TRPV1 mechanism for obesity treatment in late-stage trials.
The company faces intense competition from established GLP-1 drugs and numerous other candidates in development.
As a pre-revenue firm, it carries significant financial risk and will require further dilutive funding to advance its programs.

Competitive Landscape

Pila Pharma operates in the highly competitive obesity and diabetes markets, dominated by injectable GLP-1 receptor agonists (e.g., semaglutide, tirzepatide). Its primary differentiation is its novel oral mechanism targeting TRPV1, a pathway distinct from incretins. It competes with other oral metabolic candidates in development and must demonstrate comparable efficacy, safety, and cost advantages to capture market share.

More companies in Sweden →